123 ioflupane-CIT (DAT-SCAN) chez les patients présentant un tremblement essentiel associé à un tremblement de repos

MONTPELLIER-BU Médecine UPM (341722108) / SudocMONTPELLIER-BU Médecine (341722104) / SudocSudocFranceF

Intravenous Thrombolysis in Middle Cerebral Artery Occlusion Associated with Transient Symptoms

International audienc

Progressive ataxia related to PRRT2 gene mutation

International audienc

Individual growth monitoring of European sea bass larvae by image analysis and microsatellite genotyping

The aims of the present study were to develop non-lethal methods to identify individual fish larvae and post-larvae before tagging and accurately follow their growth characteristics. European sea bass (Dicentrarchus labrax) was used as a model species at four different ages ranging from 71 to 100 days post fertilization (dpf). Two different methods were tested for non-lethal tissue sampling from each larva for DNA analysis: 1) using a sterile absorbent paper to sample mucus and/or epithelial cells by rubbing the fish skin and 2) fin-clip of the bottom part of the caudal fin. Whatever the age of the larvae, the genotyping rate (at 12 microsatellite markers) was low with the use of sterile absorbent paper but relatively high with fin-clip sampling at 80 and 87 dpf (on average 17 and 63% of the loci genotyped for sterile paper and fin clips, respectively). Several measurements were performed on digital pictures of sea bass larvae to model body weight. Using area, perimeter, length, height and volume, it was possible to estimate body weight with a coefficient of determination r2 = 0.98 on very small larvae (body weight ranging from 20.0 to 419.3 mg). The present results suggested that individual monitoring of the growth of European sea bass larvae can be achieved by combining image analysis and microsatellite genotyping as early as 87 dpf or 236 mg mean body weight

Cortical abnormalities on MRI: what a neurologist should know

International audienceCerebral cortical lesions develop in many disorders including vascular diseases, metabolic disorders, inflammatory diseases, tumours, infections and genetic disorders. In some diseases, the cortical involvement is typical and sometimes isolated, while in others the cortical lesions occur only occasionally (often alongside other typical extra-cortical lesions).In this review, we discuss mainly the MRI characteristics of cortical lesions encountered in different disorders. From a radiological perspective, identifying the origin of a cortical lesion depends on the exact localisation of signal changes, the presence of extra-cortical lesions, the signal changes on different MRI sequences and the evolution of the radiological abnormalities over time. These must be interpreted in light of the history and clinical state of the patient, and other radiological and non-radiological examinations

Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine

Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX® (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN® (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2–13) and 21 (6–68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN® thus seems to represent an effective and sustained prophylactic treatment of chronic migraine

Ipsilateral Uveitis and Optic Neuritis in Multiple Sclerosis

Background. Uveitis is 20 times more frequent in multiple sclerosis (MS) patients than in the general population. Methods. A retrospective study of local multiple sclerosis (n=700) and uveitis cohorts (n=450) described the ophthalmological and neurological characteristics of patients with multiple sclerosis and uveitis. Results. Uveitis and multiple sclerosis were associated in seven patients. The time intervals between diagnoses of MS and uveitis ranged from 6 months to 15 years. Analysis of the patients’ characteristics revealed that multiple sclerosis was associated with an older age of onset than usually expected, that is, 39 years. Uveitis was bilateral in three cases and mainly posterior (5/10). Five patients presented with acute optic neuritis (two in one eye and three in both eyes). All eyes presenting with acute optic neuritis were also affected by uveitis (P=0.02), though not simultaneously. Conclusion. The ipsilateral association between optic neuritis and uveitis in this series of patients with multiple sclerosis may suggest a reciprocal potentiation between optic neuritis and uveitis in multiple sclerosis